Going with the Phlow
SOURCE
Pharmaceutical Commerce
Pharmaceutical Commerce
Going with the Phlow
“Established just over two years ago, Phlow quickly generated headlines, some of them controversial, as the corporation secured a contract of up to $812 million from the Trump administration to produce essential medicines that were in short supply or had vulnerable supply chains during the COVID-19 pandemic. In November 2020, however, Outsourced Pharma editor Louis Garguilo wrote of Phlow that no biopharma startup ‘has been as misconstrued, hastily judged in strategy and capability, or even labeled ‘political.'”